Compare Toronto-Dominion Bank (TD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs Viatris Inc — how do they compare? Toronto-Dominion Bank trades at $120.27 (market cap $197.03B), while Viatris Inc trades at $17.15 (market cap $19.79B). The key difference: Toronto-Dominion Bank is far larger — about 10× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| TD | VTRS | |
|---|---|---|
Market Cap | $197.03B | $19.79B |
Sector | Financials | Health |
52-Week High | $124.80 | $17.39 |
52-Week Low | $72.55 | $8.74 |
Dividend Yield | 2.62% | 2.83% |
Enterprise Value | — | $32.00B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
